{
    "info": {
        "nct_id": "NCT03072238",
        "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer",
        "inclusion_criteria": "* Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening\n* Adequate hematologic and organ function within 28 days before the first study treatment\n* Ability to comply with the study protocol, in the investigator's judgment\n* Willingness and ability of participants to use the electronic device to report selected study outcomes; Caregivers and site staff can assist with patient diary input but patient must be able to independently comprehend and answer the questionnaires\n* Life expectancy of at least 6 months\n* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm\n* For enrollment into the China extension cohort, residence in the People's Republic of China\n\nDisease-specific Inclusion Criteria:\n\n* Histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features\n* Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred) or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue accompanied by an associated pathology report (with tumor content information, Gleason score, and disease staging) for PTEN IHC and NGS testing and for other protocol-mandated secondary and exploratory assessments. If only 12-14 slides are available, the patient may still be eligible for the study, after discussion with and approval by the Medical Monitor. Cytologic or fine-needle aspiration samples are not acceptable. Tumor tissue from bone metastases is not acceptable\n* A valid PTEN IHC result (testingcentral laboratory tested with results directly sent to IxRS) (e.g., participants with an \"invalid\" or \"failed\" PTEN IHC result are not permitted to enroll)\n* Metastatic disease documented prior to randomization by clear evidence of bone lesions on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1\n* Asymptomatic or mildly symptomatic form of prostate cancer\n* Progressive disease before initiating study treatment\n* Ongoing androgen deprivation with gonadotropin-releasing hormone (GnRH) analog or bilateral orchiectomy, with serum testosterone <= 50 ng/dL (<= 1.7 nmol/L) within 28 days before randomization\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Inability or unwillingness to swallow whole pills\n* History of malabsorption syndrome or other condition that would interfere with enteral absorption\n* Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including cirrhosis, current alcohol abuse, or current known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* Need of more than 10 mg/day of prednisone or an equivalent dose of other anti-inflammatory corticosteroids as a current systemic corticosteroid therapy to treat a chronic disease (e.g., rheumatic disorder)\n* Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1, Cycle 1\n* Immunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditions\n* Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of the need for major surgery during study treatment\n* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), untreated coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), myocardial infarction or atrial thrombotic events within the past 6 months, severe unstable angina, New York Heart Association Class III and IV heart disease or depressed left ventricular ejection fraction (LVEF; previously documented LVEF < 50% without documentation of recovery), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome\n* History of another malignancy within 5 years prior to randomization, except for either adequately treated non-melanomatous carcinoma of the skin, adequately treated melanoma in situ, adequately treated non-muscle-invasive urothelial carcinoma of the bladder (Tis, Ta, and low grade T1 tumors), or other malignancies where the patient has undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to have a recurrence rate of <5% at 5 years\n* Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications.\n\nDisease-Specific Exclusion Criteria:\n\n* Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the prostate\n* Any therapy including chemotherapy (e.g., docetaxel) or biological therapy (e.g., vaccine, immunotherapy) for the treatment of castration-resistant prostate cancer. Previous treatment with flutamide, steroidal anti-androgens, androgens, estrogens, bicalutamide, nilutamide, or 5-α reductase inhibitor is permitted.\n* Use of opioid medications for cancer-related pain, including codeine and dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1\n* Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis. Previous treatment with itraconazole and fluconazole is permitted.\n* Prior treatment with enzalutamide or other potent androgen-receptor blockers, approved or experimental (e.g., ARN-509, ODM-201, or galeterone)\n* Prior treatment with flutamide (Eulexin®), steroidal anti-androgens (e.g., cyproterone acetate, chlormadinone acetate), androgens, or estrogens treatment within 4 weeks of Cycle 1, Day 1\n* Prior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks of Cycle 1, Day 1\n* Prior treatment with 5-alpha reductase inhibitors within 4 weeks of Cycle 1, Day 1\n* Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and strontium-89). Radiopharmaceuticals for the purpose of imaging are permitted. Focal palliative radiation to treat cancer-related pain is permitted provided that the last treatment with radiation is at least 14 days prior to Cycle 1, Day 1.\n* Prior treatment with approved or experimental therapeutic agents with known inhibition of the PI3K pathway, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitors\n* Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day 1\n* Known untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsant medications or corticosteroids for symptomatic control); a CT or MRI scan of the brain will be performed at screening if required by the local health authority\n* Any chronic therapy or use of food supplements that are strong CYP3A4/5 inducers or inhibitors or sensitive substrates of CYP3A or CYP2D6 with a narrow therapeutic window\n\nAbiraterone-Specific Exclusion Criteria:\n\n* Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg)\n* History of pituitary or adrenal dysfunction\n* Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical therapy\n\nIpatasertib-Specific Exclusion Criteria:\n\n* Type 1 or Type 2 diabetes mellitus requiring insulin at study entry\n* History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis), active bowel inflammation (e.g., diverticulitis)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For enrollment into the China extension cohort, residence in the People's Republic of China",
            "criterions": [
                {
                    "exact_snippets": "enrollment into the China extension cohort, residence in the People's Republic of China",
                    "criterion": "residence",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "People's Republic of China"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A valid PTEN IHC result (testingcentral laboratory tested with results directly sent to IxRS) (e.g., participants with an \"invalid\" or \"failed\" PTEN IHC result are not permitted to enroll)",
            "criterions": [
                {
                    "exact_snippets": "A valid PTEN IHC result ... participants with an \"invalid\" or \"failed\" PTEN IHC result are not permitted to enroll",
                    "criterion": "PTEN IHC result",
                    "requirements": [
                        {
                            "requirement_type": "validity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressive disease before initiating study treatment",
            "criterions": [
                {
                    "exact_snippets": "Progressive disease before initiating study treatment",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "before initiating study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of at least 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed prostate adenocarcinoma",
                    "criterion": "prostate adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "without neuroendocrine differentiation",
                    "criterion": "neuroendocrine differentiation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without ... small-cell features",
                    "criterion": "small-cell features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm",
            "criterions": [
                {
                    "exact_snippets": "Agreement to remain abstinent (refrain from heterosexual intercourse)",
                    "criterion": "sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from heterosexual intercourse",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use contraceptive measures",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "use of contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to refrain from donating sperm",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating sperm",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Asymptomatic or mildly symptomatic form of prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Asymptomatic or mildly symptomatic form of prostate cancer",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "symptom severity",
                            "expected_value": [
                                "asymptomatic",
                                "mildly symptomatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening",
            "criterions": [
                {
                    "exact_snippets": "Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic and organ function within 28 days before the first study treatment",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function within 28 days before the first study treatment",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before first study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... organ function within 28 days before the first study treatment",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before first study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing androgen deprivation with gonadotropin-releasing hormone (GnRH) analog or bilateral orchiectomy, with serum testosterone <= 50 ng/dL (<= 1.7 nmol/L) within 28 days before randomization",
            "criterions": [
                {
                    "exact_snippets": "Ongoing androgen deprivation with gonadotropin-releasing hormone (GnRH) analog or bilateral orchiectomy",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "GnRH analog",
                                "bilateral orchiectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "serum testosterone <= 50 ng/dL (<= 1.7 nmol/L) within 28 days before randomization",
                    "criterion": "serum testosterone",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 50,
                                        "unit": "ng/dL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1.7,
                                        "unit": "nmol/L"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days before randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred) or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue accompanied by an associated pathology report (with tumor content information, Gleason score, and disease staging) for PTEN IHC and NGS testing and for other protocol-mandated secondary and exploratory assessments. If only 12-14 slides are available, the patient may still be eligible for the study, after discussion with and approval by the Medical Monitor. Cytologic or fine-needle aspiration samples are not acceptable. Tumor tissue from bone metastases is not acceptable",
            "criterions": [
                {
                    "exact_snippets": "Consent to provide a formalin-fixed paraffin-embedded (FFPE) tissue block (preferred) or a minimum of 15 (20 preferred) freshly cut unstained tumor slides from the most recently collected, available tumor tissue",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sample_type",
                            "expected_value": [
                                "formalin-fixed paraffin-embedded (FFPE) tissue block",
                                "freshly cut unstained tumor slides"
                            ]
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "slides"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": "most recently collected"
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "accompanied by an associated pathology report (with tumor content information, Gleason score, and disease staging)",
                    "criterion": "pathology report",
                    "requirements": [
                        {
                            "requirement_type": "accompaniment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "content",
                            "expected_value": [
                                "tumor content information",
                                "Gleason score",
                                "disease staging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for PTEN IHC and NGS testing and for other protocol-mandated secondary and exploratory assessments",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "testing",
                            "expected_value": [
                                "PTEN IHC",
                                "NGS",
                                "other protocol-mandated secondary and exploratory assessments"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "If only 12-14 slides are available, the patient may still be eligible for the study, after discussion with and approval by the Medical Monitor.",
                    "criterion": "tumor tissue slides (exception)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "slides"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "slides"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "approval",
                            "expected_value": "Medical Monitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cytologic or fine-needle aspiration samples are not acceptable.",
                    "criterion": "cytologic or fine-needle aspiration samples",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumor tissue from bone metastases is not acceptable",
                    "criterion": "tumor tissue from bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to comply with the study protocol, in the investigator's judgment",
            "criterions": [
                {
                    "exact_snippets": "Ability to comply with the study protocol",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the investigator's judgment",
                    "criterion": "investigator's judgment of compliance ability",
                    "requirements": [
                        {
                            "requirement_type": "investigator assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness and ability of participants to use the electronic device to report selected study outcomes; Caregivers and site staff can assist with patient diary input but patient must be able to independently comprehend and answer the questionnaires",
            "criterions": [
                {
                    "exact_snippets": "Willingness and ability of participants to use the electronic device to report selected study outcomes",
                    "criterion": "use of electronic device to report study outcomes",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patient must be able to independently comprehend and answer the questionnaires",
                    "criterion": "comprehension and answering of questionnaires",
                    "requirements": [
                        {
                            "requirement_type": "ability (independent)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic disease documented prior to randomization by clear evidence of bone lesions on bone scan and/or measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Metastatic disease documented prior to randomization",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "clear evidence of bone lesions on bone scan",
                    "criterion": "bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "evidence on bone scan",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable soft tissue disease by computed tomography (CT) and/or magnetic resonance imaging (MRI) (at least one target lesion) according to RECIST v1.1",
                    "criterion": "measurable soft tissue disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "computed tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        },
                        {
                            "requirement_type": "minimum number of target lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "target lesion"
                            }
                        },
                        {
                            "requirement_type": "criteria standard",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Disease-specific Inclusion Criteria:",
            "criterions": [
                {
                    "exact_snippets": "Disease-specific Inclusion Criteria",
                    "criterion": "disease-specific inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical therapy",
            "criterions": [
                {
                    "exact_snippets": "Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical therapy",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Disease-Specific Exclusion Criteria:",
            "criterions": [
                {
                    "exact_snippets": "Disease-Specific Exclusion Criteria",
                    "criterion": "disease-specific exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of opioid medications for cancer-related pain, including codeine and dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1",
            "criterions": [
                {
                    "exact_snippets": "Use of opioid medications for cancer-related pain, including codeine and dextropropoxyphene, currently or any time within 4 weeks of Day 1, Cycle 1",
                    "criterion": "use of opioid medications for cancer-related pain",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "currently"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks before Day 1, Cycle 1"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with 5-alpha reductase inhibitors within 4 weeks of Cycle 1, Day 1",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with 5-alpha reductase inhibitors within 4 weeks of Cycle 1, Day 1",
                    "criterion": "prior treatment with 5-alpha reductase inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunocompromised status because of current known active infection with HIV or because of the use of immunosuppressive therapies for other conditions",
            "criterions": [
                {
                    "exact_snippets": "current known active infection with HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "use of immunosuppressive therapies for other conditions",
                    "criterion": "use of immunosuppressive therapies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "for other conditions"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability or unwillingness to swallow whole pills",
            "criterions": [
                {
                    "exact_snippets": "Inability ... to swallow whole pills",
                    "criterion": "ability to swallow whole pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unwillingness to swallow whole pills",
                    "criterion": "willingness to swallow whole pills",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsant medications or corticosteroids for symptomatic control); a CT or MRI scan of the brain will be performed at screening if required by the local health authority",
            "criterions": [
                {
                    "exact_snippets": "Known untreated or active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "untreated",
                                "active"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "progressing or requiring anticonvulsant medications or corticosteroids for symptomatic control",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requirement for anticonvulsant medications",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requirement for corticosteroids for symptomatic control",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a CT or MRI scan of the brain will be performed at screening if required by the local health authority",
                    "criterion": "CT or MRI scan of the brain at screening",
                    "requirements": [
                        {
                            "requirement_type": "requirement by local health authority",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis. Previous treatment with itraconazole and fluconazole is permitted.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with abiraterone or other known potent CYP17 inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis.",
                    "criterion": "prior treatment with potent CYP17 inhibitors or investigational agents that block androgen synthesis",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug names",
                            "expected_value": [
                                "abiraterone",
                                "ketoconazole",
                                "orteronel"
                            ]
                        },
                        {
                            "requirement_type": "drug class",
                            "expected_value": [
                                "potent CYP17 inhibitors",
                                "investigational agents that block androgen synthesis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous treatment with itraconazole and fluconazole is permitted.",
                    "criterion": "prior treatment with itraconazole or fluconazole",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug names",
                            "expected_value": [
                                "itraconazole",
                                "fluconazole"
                            ]
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with enzalutamide or other potent androgen-receptor blockers, approved or experimental (e.g., ARN-509, ODM-201, or galeterone)",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with enzalutamide or other potent androgen-receptor blockers, approved or experimental (e.g., ARN-509, ODM-201, or galeterone)",
                    "criterion": "prior treatment with potent androgen-receptor blockers",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug names",
                            "expected_value": [
                                "enzalutamide",
                                "ARN-509",
                                "ODM-201",
                                "galeterone",
                                "other potent androgen-receptor blockers (approved or experimental)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications.",
            "criterions": [
                {
                    "exact_snippets": "Any other diseases, cardiovascular, pulmonary, or metabolic dysfunction",
                    "criterion": "other diseases or dysfunctions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "physical examination finding ... giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications",
                    "criterion": "physical examination finding indicating contraindication or high risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participants at high risk from treatment complications",
                    "criterion": "clinical laboratory finding indicating contraindication or high risk",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Type 1 or Type 2 diabetes mellitus requiring insulin at study entry",
            "criterions": [
                {
                    "exact_snippets": "Type 1 or Type 2 diabetes mellitus",
                    "criterion": "diabetes mellitus type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "Type 1",
                                "Type 2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring insulin at study entry",
                    "criterion": "insulin requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement at study entry",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Need of more than 10 mg/day of prednisone or an equivalent dose of other anti-inflammatory corticosteroids as a current systemic corticosteroid therapy to treat a chronic disease (e.g., rheumatic disorder)",
            "criterions": [
                {
                    "exact_snippets": "Need of more than 10 mg/day of prednisone or an equivalent dose of other anti-inflammatory corticosteroids as a current systemic corticosteroid therapy",
                    "criterion": "systemic corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "corticosteroid type",
                            "expected_value": [
                                "prednisone",
                                "equivalent dose of other anti-inflammatory corticosteroids"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "to treat a chronic disease (e.g., rheumatic disorder)",
                    "criterion": "chronic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day 1",
            "criterions": [
                {
                    "exact_snippets": "Administration of an investigational therapeutic agent within 28 days of Cycle 1, Day 1",
                    "criterion": "administration of investigational therapeutic agent",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before Cycle 1, Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias, such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), untreated coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), myocardial infarction or atrial thrombotic events within the past 6 months, severe unstable angina, New York Heart Association Class III and IV heart disease or depressed left ventricular ejection fraction (LVEF; previously documented LVEF < 50% without documentation of recovery), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome",
            "criterions": [
                {
                    "exact_snippets": "History of ventricular dysrhythmias",
                    "criterion": "ventricular dysrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "risk factors for ventricular dysrhythmias",
                    "criterion": "risk factors for ventricular dysrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy)",
                    "criterion": "structural heart disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe left ventricular systolic dysfunction",
                    "criterion": "left ventricular systolic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "left ventricular hypertrophy",
                    "criterion": "left ventricular hypertrophy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)",
                    "criterion": "coronary heart disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic or with ischemia demonstrated by diagnostic testing",
                    "criterion": "coronary heart disease symptoms or ischemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction or atrial thrombotic events within the past 6 months",
                    "criterion": "myocardial infarction or atrial thrombotic events",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class III and IV heart disease",
                    "criterion": "New York Heart Association heart disease class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "depressed left ventricular ejection fraction (LVEF; previously documented LVEF < 50% without documentation of recovery)",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia)",
                    "criterion": "electrolyte abnormalities",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypokalemia",
                    "criterion": "hypokalemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypomagnesemia",
                    "criterion": "hypomagnesemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypocalcemia",
                    "criterion": "hypocalcemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of sudden unexplained death or long QT syndrome",
                    "criterion": "family history of sudden unexplained death or long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "family history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another malignancy within 5 years prior to randomization, except for either adequately treated non-melanomatous carcinoma of the skin, adequately treated melanoma in situ, adequately treated non-muscle-invasive urothelial carcinoma of the bladder (Tis, Ta, and low grade T1 tumors), or other malignancies where the patient has undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to have a recurrence rate of <5% at 5 years",
            "criterions": [
                {
                    "exact_snippets": "History of another malignancy within 5 years prior to randomization",
                    "criterion": "history of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "timing relative to randomization",
                            "expected_value": "prior to randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "except for ... adequately treated non-melanomatous carcinoma of the skin",
                    "criterion": "non-melanomatous carcinoma of the skin",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "except for ... adequately treated melanoma in situ",
                    "criterion": "melanoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "except for ... adequately treated non-muscle-invasive urothelial carcinoma of the bladder (Tis, Ta, and low grade T1 tumors)",
                    "criterion": "non-muscle-invasive urothelial carcinoma of the bladder",
                    "requirements": [
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": "adequately treated"
                        },
                        {
                            "requirement_type": "tumor stage",
                            "expected_value": [
                                "Tis",
                                "Ta",
                                "low grade T1"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "other malignancies where the patient has undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to have a recurrence rate of <5% at 5 years",
                    "criterion": "other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "therapy type",
                            "expected_value": "potentially curative"
                        },
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "recurrence rate at 5 years",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any therapy including chemotherapy (e.g., docetaxel) or biological therapy (e.g., vaccine, immunotherapy) for the treatment of castration-resistant prostate cancer. Previous treatment with flutamide, steroidal anti-androgens, androgens, estrogens, bicalutamide, nilutamide, or 5-α reductase inhibitor is permitted.",
            "criterions": [
                {
                    "exact_snippets": "Any therapy including chemotherapy (e.g., docetaxel) or biological therapy (e.g., vaccine, immunotherapy) for the treatment of castration-resistant prostate cancer.",
                    "criterion": "prior therapy for castration-resistant prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "prior receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1, Cycle 1",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring intravenous (IV) antibiotics within 14 days before Day 1, Cycle 1",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous (IV) antibiotics"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days before Day 1, Cycle 1"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Ipatasertib-Specific Exclusion Criteria:",
            "criterions": [
                {
                    "exact_snippets": "Ipatasertib-Specific Exclusion Criteria",
                    "criterion": "Ipatasertib-specific exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and strontium-89). Radiopharmaceuticals for the purpose of imaging are permitted. Focal palliative radiation to treat cancer-related pain is permitted provided that the last treatment with radiation is at least 14 days prior to Cycle 1, Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with systemic radiopharmaceuticals (e.g., radium-223 and strontium-89)",
                    "criterion": "prior treatment with systemic radiopharmaceuticals",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiopharmaceuticals for the purpose of imaging are permitted",
                    "criterion": "radiopharmaceuticals for imaging",
                    "requirements": [
                        {
                            "requirement_type": "use for imaging",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Focal palliative radiation to treat cancer-related pain is permitted provided that the last treatment with radiation is at least 14 days prior to Cycle 1, Day 1",
                    "criterion": "focal palliative radiation for cancer-related pain",
                    "requirements": [
                        {
                            "requirement_type": "use for cancer-related pain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of malabsorption syndrome or other condition that would interfere with enteral absorption",
            "criterions": [
                {
                    "exact_snippets": "History of malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other condition that would interfere with enteral absorption",
                    "criterion": "condition interfering with enteral absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Abiraterone-Specific Exclusion Criteria:",
            "criterions": [
                {
                    "exact_snippets": "Abiraterone-Specific Exclusion Criteria",
                    "criterion": "abiraterone-specific exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of the need for major surgery during study treatment",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure ... within 28 days prior to Day 1, Cycle 1",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant traumatic injury within 28 days prior to Day 1, Cycle 1",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "time since injury",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of the need for major surgery during study treatment",
                    "criterion": "anticipated need for major surgery",
                    "requirements": [
                        {
                            "requirement_type": "anticipated during study treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with approved or experimental therapeutic agents with known inhibition of the PI3K pathway, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitors",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with approved or experimental therapeutic agents with known inhibition of the PI3K pathway, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitors",
                    "criterion": "prior treatment with PI3K pathway inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent type",
                            "expected_value": [
                                "PI3K inhibitors",
                                "AKT inhibitors",
                                "mTOR inhibitors"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any chronic therapy or use of food supplements that are strong CYP3A4/5 inducers or inhibitors or sensitive substrates of CYP3A or CYP2D6 with a narrow therapeutic window",
            "criterions": [
                {
                    "exact_snippets": "Any chronic therapy or use of food supplements that are strong CYP3A4/5 inducers or inhibitors",
                    "criterion": "chronic therapy or use of food supplements",
                    "requirements": [
                        {
                            "requirement_type": "CYP3A4/5 induction",
                            "expected_value": "strong inducer"
                        },
                        {
                            "requirement_type": "CYP3A4/5 inhibition",
                            "expected_value": "strong inhibitor"
                        }
                    ]
                },
                {
                    "exact_snippets": "sensitive substrates of CYP3A or CYP2D6 with a narrow therapeutic window",
                    "criterion": "use of sensitive substrates of CYP3A or CYP2D6",
                    "requirements": [
                        {
                            "requirement_type": "substrate sensitivity",
                            "expected_value": "sensitive substrate"
                        },
                        {
                            "requirement_type": "therapeutic window",
                            "expected_value": "narrow"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks of Cycle 1, Day 1",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with bicalutamide (Casodex®) ... within 6 weeks of Cycle 1, Day 1",
                    "criterion": "prior treatment with bicalutamide",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks before Cycle 1, Day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... nilutamide (Nilandron®) within 6 weeks of Cycle 1, Day 1",
                    "criterion": "prior treatment with nilutamide",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks before Cycle 1, Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic blood pressure ≥ 160 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 160,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure ≥ 95 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 95,
                                "unit": "mmHg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant history of liver disease consistent with Child-Pugh Class B or C, including cirrhosis, current alcohol abuse, or current known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant history of liver disease consistent with Child-Pugh Class B or C",
                    "criterion": "liver disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "Child-Pugh Class B",
                                "Child-Pugh Class C"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current alcohol abuse",
                    "criterion": "alcohol abuse",
                    "requirements": [
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current known active infection with hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "current active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "current known active infection with ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "current active infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the prostate",
            "criterions": [
                {
                    "exact_snippets": "Pathologic findings consistent with small-cell or neuroendocrine carcinoma of the prostate",
                    "criterion": "pathologic findings",
                    "requirements": [
                        {
                            "requirement_type": "consistency with diagnosis",
                            "expected_value": [
                                "small-cell carcinoma of the prostate",
                                "neuroendocrine carcinoma of the prostate"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of pituitary or adrenal dysfunction",
            "criterions": [
                {
                    "exact_snippets": "History of pituitary ... dysfunction",
                    "criterion": "pituitary dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... adrenal dysfunction",
                    "criterion": "adrenal dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis), active bowel inflammation (e.g., diverticulitis)",
            "criterions": [
                {
                    "exact_snippets": "History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis)",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active bowel inflammation (e.g., diverticulitis)",
                    "criterion": "bowel inflammation",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Prior treatment with flutamide (Eulexin®), steroidal anti-androgens (e.g., cyproterone acetate, chlormadinone acetate), androgens, or estrogens treatment within 4 weeks of Cycle 1, Day 1",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with flutamide (Eulexin®) ... within 4 weeks of Cycle 1, Day 1",
                    "criterion": "flutamide (Eulexin®) treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Cycle 1, Day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with steroidal anti-androgens (e.g., cyproterone acetate, chlormadinone acetate) ... within 4 weeks of Cycle 1, Day 1",
                    "criterion": "steroidal anti-androgens treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Cycle 1, Day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with androgens ... within 4 weeks of Cycle 1, Day 1",
                    "criterion": "androgens treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Cycle 1, Day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with estrogens treatment within 4 weeks of Cycle 1, Day 1",
                    "criterion": "estrogens treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before Cycle 1, Day 1"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}